Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient

Wonseok Kang, Jinseok Kim, Sang Ho Cho, Sung Kyu Kim, Joon Chang, Moo Suk Park

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma. Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective treatment in multiple myeloma. Pulmonary complications are believed to be rare, especially interstitial lung disease. Here, we describe a patient with dyspnea and diffuse pulmonary infiltrates while receiving bortezomib and thalidomide in combination with dexamethasone for treatment-naïve multiple myeloma. Bronchoalveolar lavage demonstrated a significant decrease in the ratio of CD4: CD8 T lymphocytes (CD4/8 ratio, 0.54). Extensive workup for other causes, including infections, was negative. A lung biopsy under video-assisted thorascopic surgery revealed a diagnosis of nonspecific interstitial pneumonitis. The symptoms and imaging study findings improved after initiating steroid treatment. Physicians should be aware of this potential complication in patients receiving the novel molecular-targeted antineoplastic agents, bortezomib and thalidomide, who present with dyspnea and new pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics.

Original languageEnglish
Pages (from-to)448-450
Number of pages3
JournalYonsei medical journal
Volume51
Issue number3
DOIs
Publication statusPublished - 2010 May 1

Fingerprint

Thalidomide
Interstitial Lung Diseases
Multiple Myeloma
Lung
Dyspnea
Video-Assisted Surgery
Therapeutics
CD4-CD8 Ratio
Bronchoalveolar Lavage
Antineoplastic Agents
Dexamethasone
Steroids
Bortezomib
Anti-Bacterial Agents
Physicians
T-Lymphocytes
Biopsy
Infection
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kang, Wonseok ; Kim, Jinseok ; Cho, Sang Ho ; Kim, Sung Kyu ; Chang, Joon ; Park, Moo Suk. / Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient. In: Yonsei medical journal. 2010 ; Vol. 51, No. 3. pp. 448-450.
@article{30508cd37c24469d8f840a5ef3af6ffb,
title = "Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient",
abstract = "Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma. Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective treatment in multiple myeloma. Pulmonary complications are believed to be rare, especially interstitial lung disease. Here, we describe a patient with dyspnea and diffuse pulmonary infiltrates while receiving bortezomib and thalidomide in combination with dexamethasone for treatment-na{\"i}ve multiple myeloma. Bronchoalveolar lavage demonstrated a significant decrease in the ratio of CD4: CD8 T lymphocytes (CD4/8 ratio, 0.54). Extensive workup for other causes, including infections, was negative. A lung biopsy under video-assisted thorascopic surgery revealed a diagnosis of nonspecific interstitial pneumonitis. The symptoms and imaging study findings improved after initiating steroid treatment. Physicians should be aware of this potential complication in patients receiving the novel molecular-targeted antineoplastic agents, bortezomib and thalidomide, who present with dyspnea and new pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics.",
author = "Wonseok Kang and Jinseok Kim and Cho, {Sang Ho} and Kim, {Sung Kyu} and Joon Chang and Park, {Moo Suk}",
year = "2010",
month = "5",
day = "1",
doi = "10.3349/ymj.2010.51.3.448",
language = "English",
volume = "51",
pages = "448--450",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "3",

}

Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient. / Kang, Wonseok; Kim, Jinseok; Cho, Sang Ho; Kim, Sung Kyu; Chang, Joon; Park, Moo Suk.

In: Yonsei medical journal, Vol. 51, No. 3, 01.05.2010, p. 448-450.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient

AU - Kang, Wonseok

AU - Kim, Jinseok

AU - Cho, Sang Ho

AU - Kim, Sung Kyu

AU - Chang, Joon

AU - Park, Moo Suk

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma. Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective treatment in multiple myeloma. Pulmonary complications are believed to be rare, especially interstitial lung disease. Here, we describe a patient with dyspnea and diffuse pulmonary infiltrates while receiving bortezomib and thalidomide in combination with dexamethasone for treatment-naïve multiple myeloma. Bronchoalveolar lavage demonstrated a significant decrease in the ratio of CD4: CD8 T lymphocytes (CD4/8 ratio, 0.54). Extensive workup for other causes, including infections, was negative. A lung biopsy under video-assisted thorascopic surgery revealed a diagnosis of nonspecific interstitial pneumonitis. The symptoms and imaging study findings improved after initiating steroid treatment. Physicians should be aware of this potential complication in patients receiving the novel molecular-targeted antineoplastic agents, bortezomib and thalidomide, who present with dyspnea and new pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics.

AB - Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma. Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective treatment in multiple myeloma. Pulmonary complications are believed to be rare, especially interstitial lung disease. Here, we describe a patient with dyspnea and diffuse pulmonary infiltrates while receiving bortezomib and thalidomide in combination with dexamethasone for treatment-naïve multiple myeloma. Bronchoalveolar lavage demonstrated a significant decrease in the ratio of CD4: CD8 T lymphocytes (CD4/8 ratio, 0.54). Extensive workup for other causes, including infections, was negative. A lung biopsy under video-assisted thorascopic surgery revealed a diagnosis of nonspecific interstitial pneumonitis. The symptoms and imaging study findings improved after initiating steroid treatment. Physicians should be aware of this potential complication in patients receiving the novel molecular-targeted antineoplastic agents, bortezomib and thalidomide, who present with dyspnea and new pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics.

UR - http://www.scopus.com/inward/record.url?scp=77954302471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954302471&partnerID=8YFLogxK

U2 - 10.3349/ymj.2010.51.3.448

DO - 10.3349/ymj.2010.51.3.448

M3 - Article

VL - 51

SP - 448

EP - 450

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 3

ER -